Subsequent Event

9 Months Ended

Sep. 30, 2011

Subsequent Event: [Abstract]

Subsequent Event:

10. Subsequent Event:

On November 7, 2011, the Company announced that TTY submitted a New Drug Application for marketing authorization of BEMA^® Fentanyl to the Taiwan Food and Drug Administration. TTY is responsible for the regulatory filing of BEMA^® Fentanyl in Taiwan as well as future commercialization in that territory. The Company expects to receive a milestone payment of $0.3 million in the fourth quarter of 2011 related to this submission.